Softgels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Softgels

An industry leader since 1933, Catalent develops and manufactures over 80% of the world's Rx softgel products with 200+ products on the market in 80+ countries supplied by 11 global sites. Catalent is the world leader of softgel drug delivery technologies, the proven solution to deliver more products and better treatments by reliably solving complex bioavailability, solubility, and formulation challenges.

As the originator of the RP Scherer softgel rotary die process, coupled with over 75 years of global manufacturing expertise, Catalent manufactures softgel products across its network of facilities on 5 continents. Catalent demonstrates its softgel expertise in the following therapeutic areas: Omega-3, Vitamin-D analogs, retinoids, antivirals, and hormones. Catalent has unrivalled breadth and depth of expertise in softgel technologies to solve the toughest drug delivery challenges.

Catalent’s new, breakthrough technologies- OptiShell™ for complex fill formulations, OptiGel Bio™ for macromolecules and OptiGel Lock™ for abuse deterrence- can put even more molecules on a faster path to commercialization. Catalent’s broader range of challenging molecules, combined with deep development expertise, advanced delivery technologies and integrated supply solutions enable better outcomes for a broader range of challenging molecules.

Catalent Pharma Solutions
Website: www.catalent.com
E-mail: media@catalent.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
FindPharma Custom Search

Click here